What is PT-141? A Melanocortin Peptide Breakdown
Compound Spotlight
PT-141, also known as Bremelanotide, is one of the more clinically established compounds in this space, with an approved pharmaceutical version already on the market. This article covers what it is and how it is studied.
Quick summary
- PT-141 (Bremelanotide) is a metabolite of Melanotan II, studied for melanocortin 4 receptor activity.
- One of the few compounds in this category with an FDA-approved pharmaceutical formulation (Vyleesi).
- Studied mainly for central nervous system effects on sexual arousal pathways.
- Has a comparatively large published clinical trial dataset relative to other research peptides.
What is PT-141?
PT-141 is a synthetic peptide derived from Melanotan II, developed to act on melanocortin receptors in the central nervous system. Its melanocortin receptor 4 (MC4R) activity was later isolated as a distinct research pathway, separate from the pigmentation effects associated with Melanotan compounds.
What it is studied for
- Melanocortin receptor activity in the central nervous system
- Sexual arousal pathway research
- Hypoactive sexual desire research
- Receptor-selectivity studies distinguishing MC4R from pigmentation-related pathways
How it is thought to work
Unlike many peptides that act peripherally, PT-141 is studied for its activity in the central nervous system, specifically through melanocortin 4 receptor activation. This distinguishes it from earlier compounds in the same family, which were studied primarily for pigmentation effects through a different melanocortin receptor subtype.
Research history
PT-141 emerged from research into Melanotan II, a compound originally studied for its pigmentation effects through melanocortin receptor activation. Researchers observed that Melanotan II also produced effects on sexual arousal, which led to isolating PT-141 as a distinct metabolite studied specifically for its activity at the melanocortin 4 receptor (MC4R), separate from the pigmentation-related MC1R pathway.
This receptor-selective research path eventually led PT-141 through Phase 2 and Phase 3 clinical trials for hypoactive sexual desire disorder (HSDD) in premenopausal women, culminating in FDA approval as Vyleesi. That approval process generated a substantial body of published safety and efficacy data that is unusual for a compound in the broader research peptide category.
Where the research stands
PT-141 has one of the more developed clinical research profiles among peptides in this category, having progressed through Phase 2 and Phase 3 trials for hypoactive sexual desire disorder, leading to an approved pharmaceutical formulation. This gives researchers a comparatively large published dataset to reference.
Our PT-141
Every lot we sell is sent to an independent, third-party lab before it is listed, and the resulting Certificate of Analysis is published for that exact lot, confirming identity and purity.
For laboratory and research use only. Not for human consumption. This article is for informational purposes and summarizes existing published research; it is not medical advice.
Frequently asked questions
Is PT-141 the same as Melanotan II?
No. PT-141 is a metabolite derived from Melanotan II, but it is studied specifically for its melanocortin 4 receptor activity, which is distinct from the pigmentation-related pathway associated with Melanotan compounds.
How do I know what is actually in the vial?
Every lot we sell has a published Certificate of Analysis from an independent, third-party lab, confirming both identity and purity. You can look up any lot number directly on our site.
